Home / About Us / 


The primary objective of this project is the establishment of human induced pluripotent stem cells  (hIPSCs) and human neural stem cells (hNSCs) lines, along with Beta-pancreatic human cells. These cells will undergo cGMP certification, making them suitable for Advanced Cell Therapies (ACT) in humans. In addition, we aim to develop clinical trials for neurological disorders, including but not limited to Multiple Sclerosis and Amyotrophic lateral sclerosis and Type 1 Diabetes. The availability of autologous hIPSCs will also provide the basis for implementing a vast array of ACT for the diseases afflicting all bodily tissue and organs.

The objectives of this project encompass both fundamental and applied research on adaptive immunity in the contexts of cancer, autoimmunity, and aging. Specific focus areas include Type 1 diabetes, multiple sclerosis, tumor-associated antigens, T cell memory in aging, and T cell clonal fates. Additionally, the project investigates graft engineering in the context of auto-Hematopoietic Stem Cell Transplantation.

Our team leverages computer technology to analyze and disseminate genetic and genomic data. We specialize in genomics data analysis, minimal residual disease (MRD), immune repertoires, and advanced sequencing techniques. By conducting top-level research on adaptive immunity, facilitating the clinical implementation of advanced techniques, and introducing MRD diagnosis in the UAE, our project significantly enhances disease understanding and clinical solutions.

The main objectives of the project are centered around new-generation cell therapy and organ regeneration, with a specific focus on addressing diabetes mellitus (Type 1 and 2) and kidney disease. The general goals include developing next-generation cell therapy for Type 1 Diabetes (T1D) utilizing human induced pluripotent stem cells (hiPSCs) derived from senescence-resistant β cells. Additionally, the project aims to discover a selective drug for treating Type 2 Diabetes (T2D) by suppressing senescent β cells. Lastly, the objectives involve the development of methods for differentiating renal progenitor cells from hiPSCs, contributing to advancements in kidney disease treatments.

The primary goal of this project is to generate CAR-T cells designed to target specific B-cell antigens, as well as tumor-infiltrating lymphocytes (TILs). The objective is to eliminate both general B-cells and specific B-cell clones associated with disease, aiming to disrupt their role in the pathology of the condition.

Focusing on two key areas: Autoimmune profiling and cutting-edge cellular therapies. Through extensive research, we aim to unravel the triggers and genetic basis of autoimmune diseases, particularly Type 1 Diabetes (T1D). By analyzing autoimmune T-cells, we gain deeper insights into these complex conditions. Additionally, our state-of-the-art GMP facility is dedicated to the production of advanced cellular therapies.

We aim to provide the UAE population with innovative biological treatments for genetic and acquired disease, such as sickle cell and B-thalassemia. The goal is to customize gene therapy by modifying cells and administer back to the patient.